You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
S 32212 hydrochloride
Biological Activity for S 32212 hydrochloride
S 32212 hydrochloride is an inverse agonist of 5-HT2C receptors (pKi = 8.18 at human 5-HT2C INI receptors). Also an antagonist of human α2-adrenoceptors. Displays negligible affinity for α1A-adrenoceptors, histamine H1 receptors and muscarinic M1 receptors.
Technical Data for S 32212 hydrochloride
|Storage||Desiccate at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for S 32212 hydrochloride
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions for S 32212 hydrochloride
The following data is based on the product molecular weight 452.98. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|0.25 mM||8.83 mL||44.15 mL||88.3 mL|
|1.25 mM||1.77 mL||8.83 mL||17.66 mL|
|2.5 mM||0.88 mL||4.42 mL||8.83 mL|
|12.5 mM||0.18 mL||0.88 mL||1.77 mL|
Product Datasheets for S 32212 hydrochloride
References for S 32212 hydrochloride
References are publications that support the biological activity of the product.
Millan et al (2012) S32212, a novel serotonin type 2C receptor inverse agonist/α2-adrenoceptor antagonist and potential antidepressant: I. A mechanistic characterization. J.Pharmacol.Exp.Ther. 340 750 PMID: 22178752
Dekeyne et al (2012) S32212, a novel serotonin type 2C receptor inverse agonist/α2-adrenoceptor antagonist and potential antidepressant: II. A behavioral, neurochemical, and electrophysiological characterization. J.Pharmacol.Exp.Ther. 340 765 PMID: 22178753
If you know of a relevant reference for S 32212 hydrochloride, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: S 32212 hydrochloride, S 32212 hydrochloride supplier, S32212, antidepressants, 5-HT2C, inverse, agonists, serotonergic, alpha2, a2, α2, adrenergics, receptors, adrenoceptors, antagonists, Receptors, Adrenergic, Alpha-2, 4508, Tocris Bioscience
Citations for S 32212 hydrochloride
Citations are publications that use Tocris products.
Currently there are no citations for S 32212 hydrochloride. Do you know of a great paper that uses S 32212 hydrochloride from Tocris? Please let us know.
Reviews for S 32212 hydrochloride
There are currently no reviews for this product. Be the first to review S 32212 hydrochloride and earn rewards!
Have you used S 32212 hydrochloride?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
5-HT Receptors Scientific Review
Written by Nicholas M. Barnes and John F. Neumaier, this review summarizes the various serotonin receptor subtypes and their importance in mediating the role of serotonin in numerous physiological and pharmacological processes. Compounds available from Tocris are listed.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.